Antibody-drug conjugates (ADC) as a new treatment modality have enabled novel, promising treatment options in lung cancer. However, biomarkers for the selection of appropriate treatments are still under development, posing novel challenges for tissue selection and development of companion diagnostics (CDx). In this review, we address the challenges and discuss best practice for fast, reliable and robust implementation of novel biomarkers in treatment selection of ADCs in lung cancer.
Keywords
